BG Negev licenses Parkinson’s drug platform

ByGLOBES CORRESPONDENT
April 11, 2012 22:17

"The success of this project should improve Parkinson’s patients’ lives," says Prof. Eliahu Heldman.

Scientists in a laboratory

DNA laboratory 311. (photo credit:iStockphoto)

BGN Technologies, the technology transfer company for Ben-Gurion University of the Negev, has signed a licensing agreement for its V-Smart drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York.

Lauren Sciences will develop the technology as a platform for treating central nervous system diseases, including Parkinson’s, Alzheimer’s, Amyotrophic Lateral Sclerosis, and brain malignancies.



Be the first to know - Join our Facebook page.


The V-Smart technology pinpoints where the drug will be released in the brain, increasing effectiveness and reducing adverse effects. VSmart technology is based on nanovesicles made of proprietary building blocks that provide high stability, large encapsulation capacity, targeting to specific cells and tissues, a controlled release mechanism, and passage through biological barriers, including the blood brain barrier (BBB).

The drug delivery platform was developed by BGU researchers Dr. Sarina Grinberg of the Department of Chemistry, Dr. Charles Linder of the Department of Biotechnology and Prof. Eliahu Heldman of the Department of Clinical Biochemistry, who also serves as Lauren Science’s chief scientific officer. Lauren Sciences will continue to conduct development activities at BGU.


“Our pre-clinical studies demonstrate that novel, nano-sized V-Smart vesicles encapsulate small molecules, peptides, proteins and nucleic acids, cross the BBB and release their encapsulated contents in the brain,” said Heldman. “Our goal is to target, protect and restore dopaminergic neurons [nerve cells] in the brain that deteriorate during the course of Parkinson’s disease. The success of this project should improve Parkinson’s patients’ lives.”

The BBB is permeable for small molecules, however an active drug delivery transport system is required for other substances. There is currently an unmet need and a great medical challenge for a safe, effective and reliable drug delivery transport system to deliver viable chemotherapeutic agents to the brain of patients with brain cancer or other CNS related clinical states.

The V-Smart platform is protected by several worldwide patents filed by BGN Technologies. Lauren Sciences was recently awarded a grant from the Michael J. Fox Foundation to develop a V-Smart therapeutic for Parkinson’s disease.
Relevant to your professional network? Please share on Linkedin

Share this article via
Related Content
The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 18 - 37
    Beer Sheva
    21 - 30
    Tel Aviv - Yafo
  • 18 - 31
    Jerusalem
    19 - 28
    Haifa
  • 26 - 39
    Elat
    22 - 37
    Tiberias